![]() |
![]() |
(11) | Number of the document | C 1292612 |
(68) | Number of the document | 1292612 |
(21) | Application number for Supplementary Protection Certificate | PA 2012 002 |
(22) | Date of filing the application | 2012-02-07 |
(41) | Date of publication of the application | 2012-03-26 |
Date of publication of SPC | 2013-06-25 | |
(24) | Date of coming into effect of SPC | 2021-05-02 |
(71) |
Theravance, Inc.,
901 Gateway Boulevard, South San Francisco, CA 94080,
US
|
(73) |
Theravance Biopharma Antibiotics IP, LLC,
901 Gateway Boulevard, South San Francisco, CA 94080,
US
|
(74) |
Liudmila GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
(93) | EU/1/11/705/001, 2011 09 02 EU/1/11/705/002, 2011-09-02 |
(94) | 2026-05-02 |
(95) | Telavancinum |
SPC lapsed (non-payment of fees for the main patent) |